Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions [Yahoo! Finance]
The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices [Yahoo! Finance]
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at Mizuho to a "hold" rating.
Bicara Therapeutics (NASDAQ:BCAX) was given a new $18.00 price target on by analysts at Mizuho.
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12